je.st
news
Tag: merck
Ahead Of Earnings: Edwards Lifesciences, Kirby Corp., Merck And Roper Industries
2013-10-24 19:47:31| Appliances - Topix.net
Earnings season is upon us again, and as companies are releasing their earnings, we are going to offer investors a brief pre-earnings analysis of current and past quarters.
Tags: ahead
industries
corp
earnings
Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices
2013-10-24 16:27:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an overview of the clinical trial program for V503, the companys investigational 9-valent human papillomavirus (HPV) vaccine, to the Advisory Committee on Immunization Practices in the United States. Merck said that the pivotal efficacy trial is complete, the primary endpoints have been met and the company expects to submit a Biologics License Application for V503 to the U.S. Language: English Contact: MerckMedia:Pamela Eisele, (908) 423-5042Imraan Munshi, (215) 652-0059Investor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
committee
practices
advisory
The Merck Manual Go-To Home Guide for Symptoms Helps Patients Assess When to Worry and When to Wait, Determine Next Steps
2013-10-23 23:04:50| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the availability of a newly published book, The Merck Manual Go-To Home Guide for Symptoms, which offers essential information on when to seek medical attention and when it may suffice for consumers to address their ailments at home. Language: English Ticker Slug: Ticker: MRK Exchange: NYSE Multimedia read more
Merck Receives Breakthrough Therapy Designation for MK-5172/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
2013-10-22 23:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection. MK-5172/MK-8742 is an all-oral combination regimen consisting of MK-5172, an investigational HCV NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 908-423-5042Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: treatment
combination
therapy
virus
Merck Presents New Pharmacokinetic Data on ISENTRESS (raltegravir) at 14th European AIDS Conference
2013-10-16 14:30:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. Company Confirms Development Program for Investigational Once Daily (QD) Dosing Regimen of ISENTRESS WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, is presenting pharmacokinetic data this week on investigational formulations of a once daily (QD) dose of ISENTRESS at the 14th European AIDS Conference (EACS), sponsored by the European AIDS Clinical Society. The meeting is currently taking place in Brussels, Belgium, Oct. 16-19, 2013. The poster presentation A Single Dose Food Effect Study of Raltegravir Formulations (Poster #PE10/17) will be presented Thursday, Oct. Language: English Contact: MerckMedia Contacts:Pam Eisele, 908-423-5042Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
conference
european
aids
Sites : [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] next »